Biopharma's M&A rate jumped 11% in 2013 with the average deal value soaring 46%, according to PricewaterhouseCoopers, and analysts expect that healthy flow to continue into the new year. Year over year, transactions spiked 24% and dollar value doubled in the fourth quarter, according to PwC's numbers, driven by an increase in divestitures and a jump in valuations. Looking forward, macro-level trends, strong public markets and easy access to financing will keep the M&A train moving in 2014, PwC figures. More